Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson's.

MLA

Brimblecombe, Katherine R., et al. “Inhibition of Striatal Dopamine Release by the L‐type Calcium Channel Inhibitor Isradipine Co‐varies with Risk Factors for Parkinson’s.” European Journal of Neuroscience, vol. 59, no. 6, Mar. 2024, pp. 1242–59. EBSCOhost, https://doi.org/10.1111/ejn.16180.

APA

Brimblecombe, K. R., Connor, R. N., Bataille, C. J. R., Roberts, B. M., Gracie, C., O’Connor, B., te Water Naude, R., Karthik, G., Russell, A. J., Wade, M. R., & Cragg, S. J. (2024). Inhibition of striatal dopamine release by the L‐type calcium channel inhibitor isradipine co‐varies with risk factors for Parkinson’s. European Journal of Neuroscience, 59(6), 1242–1259. https://doi.org/10.1111/ejn.16180

Chicago

Brimblecombe, Katherine R., Robson, Natalie Connor, Carole J. R. Bataille, Bradley M. Roberts, Caitlin Gracie, Bethan O’Connor, Rebecca te Water Naude, et al. 2024. “Inhibition of Striatal Dopamine Release by the L‐type Calcium Channel Inhibitor Isradipine Co‐varies with Risk Factors for Parkinson’s.” European Journal of Neuroscience 59 (6): 1242–59. doi:10.1111/ejn.16180.